ClinicalTrials.gg
CompletedNCT05904470Updated Oct 21, 2025Results posted

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

A Phase 2 interventional study of Bemnifosbuvir and Ruzasvir in Chronic Hepatitis C Virus, Hepatitis C, Chronic and Hepatitis C, sponsored by Atea Pharmaceuticals, Inc.. Completed at 51 sites in 12 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
275
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Hepatitis C, Chronic with a site in Brazil — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Brazil.

Enrollment
11th of 26
275 · median 208
Started
2023
the only one that year
Phase 2
3 of 32
none open now
Registered
32nd of 32
by date
Lead sponsor
1 of 32
Atea Pharmaceuticals, Inc.

Among the 32 studies in Hepatitis C, Chronic with a site in Brazil, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 2, and was the 32nd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 32 studies in Hepatitis C, Chronic with a site in Brazil is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in Hepatitis C, Chronic with a site in Brazil as a file.
02

Study summary

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

03

Conditions studied

  • Chronic Hepatitis C Virus
  • Hepatitis C, Chronic
  • Hepatitis C
  • Hepatic Cirrhosis
  • HCV
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written
  • Male or female subjects between ≥ 18 years of age (or the legal age of consent per local regulations) and ≤ 85 years of age
  • Female subjects of : agreement to remain abstinent (refrain from heterosexual intercourse) or to the use of an acceptable effective
  • Females must have a negative pregnancy test at Screening and at Day 1 prior to dosing
  • Subjects must be direct-acting antiviral (DAA)-treatment-naïve, defined as never exposed to an approved or experimental DAA for
  • Documented medical history compatible with chronic HCV
  • Liver disease staging assessment as follows:

    • Absence of cirrhosis (F0 to F3)
    • Compensated cirrhosis (F4)

Exclusion criteria

Exclusion Criteria:

  • Female subject is pregnant or breastfeeding
  • Co-infected with virus (HBV; positive for hepatitis B surface antigen [HBsAg]) and/or (HIV)
  • Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator
  • Prior exposure to any DAA
  • Use of other drugs within 30 days of dosing or plans to enroll in another clinical trial of an investigational agent while participating in the present study
  • Subject with known allergy to the study medications or any of their components
  • History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal hypertension or hepatic insufficiency
  • Cirrhotic and has a score >6, corresponding to a Child-Pugh Class B or C
  • History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC
  • Any other medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    Bemnifosbuvir and Ruzasvir

    Bemnifosbuvir (BEM; AT-527) Tablets Ruzasvir (RZR; AT-038) Capsules

    Drug: Bemnifosbuvir · Drug: Ruzasvir

Interventions

  • 550 mg administered orally once a day (QD) for 8 weeks

    Also known as: AT-527

  • 180 mg administered orally once a day (QD) for 8 weeks

    Also known as: AT-038

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)

    SVR12 defined as plasma hepatitis C virus (HCV) RNA less than the lower limit of quantitation (\<LLOQ) at 12 weeks post-treatment

    Time frame: Day 1 through 12 weeks after end of treatment

Secondary outcomes

  1. Percentage of Subjects Experiencing Virologic Failure

    Virologic failure defined as a confirmed 1 log10 increase in HCV RNA from post-baseline nadir, or confirmed increase in HCV RNA ≥ LLOQ in any subject who achieved HCV RNA \< LLOQ.

    Time frame: Day 1 through 12 weeks after end of treatment

  2. Percentage of Subjects Achieving Sustained Virologic Response at 24 Weeks Post-treatment (SVR24)

    SVR24 defined as plasma HCV RNA less than the lower limit of quantitation (\<LLOQ) at 24 weeks post-treatment

    Time frame: Day 1 through 24 weeks after end of treatment

07

Results

Posted Oct 21, 2025
Limitations and caveats
This was a single arm study. Results will need to be confirmed in larger, controlled randomized trials.

Participant flow

Participant flow — Overall Study
MilestoneBEM+RZR
Started275
Completed255
Not completed20

Outcome measures

PrimaryPercentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)

SVR12 defined as plasma hepatitis C virus (HCV) RNA less than the lower limit of quantitation (\<LLOQ) at 12 weeks post-treatment

Time frame:
Day 1 through 12 weeks after end of treatment
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)
ParticipantsBEM+RZR
Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12)210
SecondaryPercentage of Subjects Experiencing Virologic Failure

Virologic failure defined as a confirmed 1 log10 increase in HCV RNA from post-baseline nadir, or confirmed increase in HCV RNA ≥ LLOQ in any subject who achieved HCV RNA \< LLOQ.

Time frame:
Day 1 through 12 weeks after end of treatment
Reported as:
Count of participants · Participants
Percentage of Subjects Experiencing Virologic Failure
ParticipantsBEM+RZR
Percentage of Subjects Experiencing Virologic Failure5
SecondaryPercentage of Subjects Achieving Sustained Virologic Response at 24 Weeks Post-treatment (SVR24)

SVR24 defined as plasma HCV RNA less than the lower limit of quantitation (\<LLOQ) at 24 weeks post-treatment

Time frame:
Day 1 through 24 weeks after end of treatment
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving Sustained Virologic Response at 24 Weeks Post-treatment (SVR24)
ParticipantsBEM+RZR
Percentage of Subjects Achieving Sustained Virologic Response at 24 Weeks Post-treatment (SVR24)206

Adverse events

Collected over Treatment-emergent adverse events were collected through 4 weeks post-treatment and serious adverse events were collected through 24 weeks post-treatment.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BEM+RZR5/275 (1.8%)19/275 (6.9%)64/275 (23.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventBEM+RZR
OverdoseInjury, poisoning and procedural complications3/275
OsteoarthritisMusculoskeletal and connective tissue disorders2/275
Atrioventricular block completeCardiac disorders1/275
PyrexiaGeneral disorders1/275
Abscess limbInfections and infestations1/275
Dengue feverInfections and infestations1/275
Oesophageal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/275
Behaviour disorderPsychiatric disorders1/275
Substance-induced psychotic disorderPsychiatric disorders1/275
Urinary tract obstructionRenal and urinary disorders1/275
Most frequent other events
Most frequent other events
EventBEM+RZR
HeadacheNervous system disorders24/275
NauseaGastrointestinal disorders22/275
DyspepsiaGastrointestinal disorders12/275
VomitingGastrointestinal disorders12/275
PyrexiaGeneral disorders11/275
DiarrhoeaGastrointestinal disorders10/275
FatigueGeneral disorders7/275
Abdominal pain upperGastrointestinal disorders6/275

Baseline characteristics

Age, Continuous
Age, Continuous(years)BEM+RZR
Mean49.6 ± 13.02
Sex: Female, Male
Sex: Female, Male(Participants)BEM+RZR
Female131
Male144
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BEM+RZR
American Indian or Alaska Native1
Asian55
Native Hawaiian or Other Pacific Islander0
Black or African American11
White192
More than one race3
Unknown or Not Reported13
Genotype (GT)
Genotype (GT)(Participants)BEM+RZR
GT1189
GT27
GT377
GT42
Compensated Cirrhosis
Compensated Cirrhosis(Participants)BEM+RZR
Count of participants37
08

Study locations

51 sites
  • Atea Study Site
    San Antonio, Texas 78215, United States
  • Atea Study Site
    Manaus, Amazonas 69040-000, Brazil
  • Atea Study Site
    Salvador, Estado de Bahia 41920-900, Brazil
  • Atea Study Site
    Brasília, Federal District 70200-730, Brazil
  • Atea Study Site
    Rio de Janeiro, Rio Do Janeiro 04037-030, Brazil
  • Atea Study Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
  • Atea Study Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Atea Study Site
    Porto Velho, Rondônia 78918-791, Brazil
  • Atea Study Site
    Boa Vista, Roraima 69304-015, Brazil
  • Atea Study Site
    Botucatu, São Paulo 18618-970, Brazil
  • Atea Study Site
    Ijuí, São Paulo 98700-000, Brazil
  • Atea Study Site
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Atea Study Site
    São Paulo, São Paulo 04119-001, Brazil
  • Atea Study Site
    São Paulo, São Paulo 05403-000, Brazil
  • Atea Study Site
    Sorocaba, São Paulo 18052-210, Brazil
  • Atea Study Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • Atea Study Site
    Toronto, Ontario M5G 2C4, Canada
  • Atea Study Site
    Rajkot, Gujarat 360005, India
  • Atea Study Site
    Surat, Gujarat 395002, India
  • Atea Study Site
    Belagavi, Karnataka 590010, India
  • Atea Study Site
    Nagpur, Maharashtra 440010, India
  • Atea Study Site
    Kolkata, West Bengal 700020, India
  • Atea Study Site
    Quatre Bornes, 72218, Mauritius
  • Atea Study Site
    Chisinau, 2025, Moldova
  • Atea Study Site
    Karachi, 74800, Pakistan
  • Atea Study Site
    Karachi, 75600, Pakistan
  • Atea Study Site
    Baguio City, 35100, Philippines
  • Atea Study Site
    Iloilo City, 5000, Philippines
  • Atea Study Site
    Mabalacat, 2023, Philippines
  • Atea Study Site
    Bucharest, BUC 022328, Romania
  • Atea Study Site
    Bucharest, BUC 30303, Romania
  • Atea Study Site
    Constanța, CON 900709, Romania
  • Atea Study Site
    Craiova, DOL 200073, Romania
  • Atea Study Site
    Bucharest, 21105, Romania
  • Atea Study Site
    Bloemfontein, Free State 9301, South Africa
  • Atea Study Site
    Johannesburg, Gauteng 2193, South Africa
  • Atea Study Site
    Randburg, Gauteng 2087, South Africa
  • Atea Study Site
    Somerset West, Western Cap 7130, South Africa
  • Atea Study Site
    Seoul, Gyeonggi-do 120-752, South Korea
  • Atea Study Site
    Yangsan, Gyeongsangnam 626-770, South Korea
  • Atea Study Site
    Busan, 47392, South Korea
  • Atea Study Site
    Busan, 49241, South Korea
  • Atea Study Site
    Seoul, 5505, South Korea
  • Atea Study Site
    Seoul, 6351, South Korea
  • Atea Study Site
    Adana, 1130, Turkey (Türkiye)
  • Atea Study Site
    Ankara, 6100, Turkey (Türkiye)
  • Atea Study Site
    Ankara, 6230, Turkey (Türkiye)
  • Atea Study Site
    Ankara, 6800, Turkey (Türkiye)
  • Atea Study Site
    Denizli, 20070, Turkey (Türkiye)
  • Atea Study Site
    Izmir, 35100, Turkey (Türkiye)
  • Atea Study Site
    Kayseri, 38010, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2024, 18 months.

Results were first posted in Oct 2025, 10 months after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 18 months is above that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 15, 2023
StartActual
May 30, 2023
Primary completionActual
Dec 9, 2024
CompletionActual
Jan 28, 2025
Results first posted
Oct 21, 2025
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05904470
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
May 30, 2023
Primary completion
Dec 9, 2024
Completion
Jan 28, 2025
Results posted
Oct 21, 2025
Last update
Oct 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bemnifosbuvir · Ruzasvir

Start the discussion